DUBLIN--(BUSINESS WIRE)--Nov 8, 2019--

The "Neurontin- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

"Neurontin Drug Insight, 2019" highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.

The report covers the Global Market Assessment of the Neurontin covering the historical global sales and also provides the Neurontin sales estimation during the forecasted period (2019-2021). The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country. In addition to this, the report also provides the SWOT analysis for Neurontin and emerging therapies in this space.

Scope

  • A review of the Neurontin, based on information derived from company and industry-specific sources
  • Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
  • Coverage of the Drug Master Files and API Manufacturers by country
  • Patent Expiry Timeline and Exclusivity Details
  • Route of Synthesis of the API
  • Forecasted Sales Figure from 2019-2021
  • Market competition and emerging therapies
  • SWOT Analysis

Reasons to Buy

  • Establish a comprehensive understanding of Neurontin
  • Access to drug`s API manufacturers details to devise API procurement strategy for generic development
  • Plan developmental timelines around drug`s patents for the major markets- US and EU
  • Understand Neurontin`s current and future growth through its historical and forecasted sales
  • Identify and understand the current in-market competitors for the drug
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Identify and plan ahead for prospective emerging players and their products operating in the same space as the drug
  • Identify opportunities in the same area as Neurontin with SWOT analysis

Key Topics Covered:

1. Report Introduction

2. Neurontin- Overview

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Regulatory Milestones by Region
  • Deals and Partnerships

3. Product Details

4. Neurontin Sales Assessment

  • Historical Sales
  • Forecasted Sales

5. Patent Details

6. Global API Manufacturers Assessment

  • Active Pharmaceutical Ingredient (API) Manufacturers by Country
  • Active Pharmaceutical Ingredient (API) Manufacturers by Region

7. Market Competition

8. Emerging Therapies

  • Product Description
  • Research and Development
  • Product Development Activities

9. SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/26v9k2

View source version on businesswire.com:https://www.businesswire.com/news/home/20191108005388/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/08/2019 10:22 AM/DISC: 11/08/2019 10:22 AM

http://www.businesswire.com/news/home/20191108005388/en

Copyright Business Wire 2019.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for Reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.